At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
imatinib mesylate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Imatinib Mesylate (STI571;NSC#716051:IND 61135) in Patients With Inoperable AJCC Stage III or IV Melanoma Harboring Somatic Alterations of C-KIT
In Brief
A Phase 2 clinical trial evaluating imatinib mesylate and laboratory biomarker analysis for Acral Lentiginous Malignant Melanoma and 5 related conditions. Completed, enrolled 30 participants across 8 sites.
Detailed Summary
This phase II trial is studying how well imatinib mesylate works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcral Lentiginous Malignant Melanoma, Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2007
First PostedMay 2007
Primary CompletionDec 2013
Study CompletionOct 2014
TodayJul 2026
First PostedMay 7, 2007
Enrollment StartApr 1, 2007
Primary CompletionDec 1, 2013
Study CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 19.2 years ago
Interventions
imatinib mesylatedrug
Given orally
laboratory biomarker analysisother
Correlative studies